Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)

Basit Öğe Kaydı
dc.contributor.authorIcli, Fikri
dc.contributor.authorAltundag, Kadri
dc.contributor.authorAkbulut, Hakan
dc.contributor.authorPaydas, Semra
dc.contributor.authorBasaran, Gul
dc.contributor.authorSaip, Pinar
dc.contributor.authorDogu, Gamze G.
dc.date.accessioned2024-04-24T16:02:47Z
dc.date.available2024-04-24T16:02:47Z
dc.date.issued2015
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground Optimal duration of adjuvant trastuzumab in early breast cancer is an unresolved issue. In this observational study, we compared the outcome of 9 weeks and 1 year adjuvant trastuzumab in early breast cancer patients in Turkey. Methods Records of 680 patients with HER2-positive early breast cancer who received adjuvant trastuzumab plus chemotherapy were obtained and patients were followed up to compare the disease-free survival (DFS) outcome of 9 weeks versus 1 year trastuzumab. Results Nine weeks and 1 year trastuzumab was given to 202 (29.7 %) and 478 (70.3 %) patients, respectively. There was a significantly lower rate of patients with negative lymph nodes in the 9-week trastuzumab group. At median 3 years of follow-up from the date of starting trastuzumab, the DFS rates were 88.6 and 85.6 %, respectively (p = 0.670). When adjusted for all the prognostic factors that were significant on univariate analysis, again there was no significant difference in DFS between the groups (HR 0.675; 95 % CI 0.370-1.231; p = 0.200). Cardiac toxicity defined as a >= 15 % decrease in LVEF was significantly higher in the 1-year trastuzumab group (1.88 % versus none for 1-year and 9-week trastuzumab groups, respectively; p = 0.050). Conclusion The results of this observational study suggest that DFS outcome of 9 weeks of adjuvant trastuzumab may be comparable to 1 year adjuvant trastuzumab: this needs confirmation by randomized trials.en_US
dc.description.sponsorshipTurkish Medical Oncoloy Societyen_US
dc.description.sponsorshipFinancial support for statistical analysis was obtained from the Turkish Medical Oncoloy Society.en_US
dc.identifier.doi10.1007/s12282-013-0506-y
dc.identifier.endpage485en_US
dc.identifier.issn1340-6868
dc.identifier.issn1880-4233
dc.identifier.issue5en_US
dc.identifier.pmid24338610en_US
dc.identifier.scopus2-s2.0-84940908211en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage480en_US
dc.identifier.urihttps://doi.org/10.1007/s12282-013-0506-y
dc.identifier.urihttps://hdl.handle.net/11468/14913
dc.identifier.volume22en_US
dc.identifier.wosWOS:000363722200006
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSpringer Japan Kken_US
dc.relation.ispartofBreast Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdjuvant Treatmenten_US
dc.subjectNine Weeks Trastuzumaben_US
dc.subjectCardiotoxicityen_US
dc.subjectEarly Breast Canceren_US
dc.titleNine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG)en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu